Fri, Apr 18, 2014, 11:54 PM EDT - U.S. Markets closed for Good Friday

Recent

% | $
Quotes you view appear here for quick access.

Sangamo Biosciences Inc. Message Board

  • gswkool gswkool Mar 8, 2013 4:24 PM Flag

    UPDATE: Wedbush Raises PT to $13 on Sangamo BioSciences on HIV Progress, Time Value

    FYI below....{pls stop talking about AF altogether pls....no more posts.., you're psychologically enforcing his need for attention....much like how infant mentalities operate}

    10:50a ET March 7, 2013 (Benzinga) Wedbush maintained Sangamo BioSciences (NASDAQ: SGMO) with an Outperform rating and raised the price target from $10.00 to $13.00.

    Wedbush said, "Sangamo presented immunologic results supporting previous observations about the functionality and durability of SB-728-T modified T-cells at the 20th Conference on Retroviruses and Opportunistic Infections (CROI). … We are reiterating our OUTPERFORM rating and increasing our fair value to $13 from $10 due to HIV progress, error correction, and time value. By focusing on CCR5 heterozygotes, we increased our peak penetration and net peak annual worldwide revenues to Sangamo to about $656 million from about $500 million."

    Sangamo BioSciences closed at $10.26 on Wednesday.

 
SGMO
13.99-0.27(-1.89%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.